– Deciphex, a leading digital pathology company based in Dublin, Ireland, has announced a collaborative effort with Novartis, a prominent multinational pharmaceutical corporation.

–位于爱尔兰都柏林的领先数字病理学公司Deciphex宣布与著名跨国制药公司诺华合作。

– The strategic partnership focuses on developing innovative artificial intelligence (AI) solutions aimed at revolutionizing preclinical pathology assessments within the drug discovery and development process.

–战略伙伴关系专注于开发创新的人工智能（AI）解决方案，旨在彻底改变药物发现和开发过程中的临床前病理学评估。

Optimizing Preclinical Pathology with AI

用人工智能优化临床前病理学

The collaboration centers on creating a suite of AI-powered tools designed to streamline and enhance the evaluation of pathology data in toxicology and efficacy studies, critical phases of drug development.

该合作的中心是创建一套AI驱动的工具，旨在简化和增强毒理学和功效研究（药物开发的关键阶段）中病理学数据的评估。

Here’s how this partnership will function:

以下是这种合作关系的运作方式：

Leveraging Expertise: The collaboration combines Deciphex’s proficiency in unsupervised AI model development with Novartis’s extensive experience in AI models, digital pathology databases, and related tools.Building on Existing Assets: The project will utilize Deciphex’s existing intellectual property alongside Novartis’s resources to create potentially groundbreaking algorithms for accurate lesion identification and quantification within drug discovery applications..

利用专业知识：该合作将Deciphex在无监督人工智能模型开发方面的熟练程度与诺华在人工智能模型，数字病理学数据库和相关工具方面的丰富经验相结合。在现有资产的基础上：该项目将利用Deciphex现有的知识产权和诺华的资源，创建潜在的开创性算法，以便在药物发现应用中准确识别和量化病变。。

Combining Expertise for Innovation

结合专业知识进行创新

The collaboration will prioritize several key objectives:

合作将优先考虑几个关键目标：

AI-powered Lesion Detection Tools: Developing a comprehensive suite of AI tools specifically designed to detect lesions across various tissue types and species, applicable to both Good Laboratory Practice (GLP) and non-GLP studies.Regulatory Compliance: Ensuring the developed AI tools meet the most recent regulations and guidelines governing AI development processes, paving the way for wider adoption.Digital Pathology Archive Creation: Deciphex will leverage its next-generation scanning services to digitize Novartis’s vast collection of tissue slides, creating a valuable digital library for future research and analysis..

AI驱动的病变检测工具：开发一套全面的AI工具，专门用于检测各种组织类型和物种的病变，适用于良好实验室规范（GLP）和非GLP研究。法规遵从性：确保开发的人工智能工具符合人工智能开发过程的最新法规和指南，为更广泛的采用铺平道路。数字病理学档案创建：Deciphex将利用其下一代扫描服务对诺华的大量组织切片进行数字化，为未来的研究和分析创建一个有价值的数字图书馆。。

“This partnership underscores our commitment to advancing healthcare through the development of cutting-edge solutions that address critical challenges in drug development lifecycles.Novartis is committed to innovating AI-based approaches with potential to accelerate drug discovery and development and bring life-changing medicines to patients faster,” said  Dr.

“这种伙伴关系强调了我们通过开发尖端解决方案来推进医疗保健的承诺，这些解决方案可以解决药物开发生命周期中的关键挑战。诺华致力于创新基于人工智能的方法，有可能加速药物的发现和开发，并更快地为患者带来改变生命的药物，”Dr。

Donal O’Shea,” CEO of Deciphex..

Donal O'Shea，“Deciphex首席执行官。